

Support Requested for this Patient

☐ Reimbursement Assistant - Prescriber will Buy & Bill ☐ Reimbursement Assistant - Fill Through Specialty Pharmacy ☐ Copay Assistance ☐ Patient Engagement Services Only

Patient Information

First Name: _____ Last Name: _____ DOB: _____
Address: _____ City: _____
State: _____ ZIP: _____ Last 4 SSN: _____ US Resident: ☐ Yes ☐ No Gender: ☐ Male ☐ Female
Cell Phone: _____ Home Phone: _____ Email: _____
OK to Text? ☐ *By checking this box, I confirm this is my phone number and agree to subscribe to the Kyowa Kirin Cares Text Message program. I understand the amount of texts I receive may vary based on the progress of my enrollment. Full Text Message Program terms and conditions: https://www.kyowakirincares.com/SMS_Terms.pdf*
Preferred Contact Method: ☐ Cell Phone ☐ Home Phone ☐ Email Best Time to Call: ☐ Morning ☐ Afternoon ☐ Evening

Patient Insurance Information

— Please attach copies of cards for both primary and secondary insurance plans —

Medical Insurance Name: _____ Phone: _____
Pharmacy Insurance Name: _____ Phone: _____
Medical Plan ID #: _____ Policy Holder Name & DOB: _____
Group #: _____ Rx BIN: _____ Rx PCN: _____ Secondary Plan? ☐ Yes ☐ No
Plan Type: ☐ Private / Commercial ☐ Medicare Part D ☐ Medicare Advantage ☐ Medicaid ☐ VA or Military ☐ None – Uninsured

Prescriber Information

Prescriber Name: _____ Prescriber NPI #: _____
Prescriber DEA: _____ Prescriber SLN: _____
Facility Name: _____ Facility HIN: _____
Address: _____ City: _____
State: _____ ZIP: _____ Phone #: _____ Fax #: _____
Office Contact Name: _____ Contact Email Address: _____

Clinical Information

Primary Diagnosis Code (ICD-10): _____ Primary Diagnosis Description: _____
Allergies: _____

Prescription for POTELIGEO® (mogamulizumab-kpkc)

Rx: POTELIGEO (mogamulizumab-kpkc) – 20mg per 5mL Patient Weight: _____ kg Refills: _____
☐ Initiating Therapy – 1mg/kg IV QW for the first 5 infusions ☐ Maintenance – 1m/kg IV QOW ☐ Other (write in below)

Rx Notes: _____

I certify that the information in this Prescription & Enrollment Form is complete and accurate to the best of my knowledge. By signing this Prescription & Enrollment Form*, I certify that I have prescribed POTELIGEO (mogamulizumab-kpkc) based on my professional judgment of medical necessity, and that I will supervise the patient's medical treatment. I authorize the release of medical and/or other patient information relating to POTELIGEO therapy to agents, and service providers of Kyowa Kirin (including but not limited to AllCare Plus Pharmacy, LLC and POTELIGEO-dispensing pharmacies) to use and disclose as necessary for fulfillment of the prescription and to furnish any information on this form to the insurer of the above-named patient for the purpose of verifying benefit eligibility and obtaining coverage authorization.

Prescriber Signature: _____ Date: _____
*Original signature is required – *If required by applicable law, please attach copies of all prescriptions on official state prescription forms*

Patient Authorization

By signing this Authorization, I authorize each of my prescribers, pharmacists, including any specialty pharmacy that receives my prescription for POTELIGEO (mogamulizumab-kpkc) and other healthcare providers (together “Healthcare Providers”) and each of my health insurers (together, “Insurers”) to disclose my Protected Health Information, including but not limited to medical records, information related to my medical condition and treatment, my health insurance coverage, my name, address, telephone number, Social Security number, insurance plan and or group numbers (together, “Protected Health Information”) to Kyowa Kirin, its affiliated companies, vendors, agents, collaboration partners, and representatives (together, “Kyowa Kirin”) including providers of alternate sources of funding for prescription drug costs, and other service providers supporting Kyowa Kirin Cares Support Services (the “Program”) for Healthcare Providers and patients for the purposes described below.

Specifically, I authorize disclosure of my Protected Health Information in order to:

- I. Enroll me in, and contact me about the Program, including online support, financial assistance services, co-pay assistance, specialist services, and compliance and persistency services,
- II. Communicate with my Healthcare Providers and Insurers about benefits, coverage and medical care, including compliance with Product treatments,
- III. Locate a specialty pharmacy that can fill my prescription and facilitate dispensing of my prescription by such pharmacy,
- IV. Provide me with educational materials, information and services related to my treatment experience with POTELIGEO and my condition,
- V. Contact me and leave messages about my use of POTELIGEO and my medical care,
- VI. Verify, investigate, assist with, and coordinate my coverage for POTELIGEO with my Insurers,
- VII. Coordinate prescription fulfillment
- VIII. Conduct surveys, data analytics, market research and other internal business activities related to the Program, POTELIGEO, and other Kyowa Kirin products and programs, and
- IX. Contact me as otherwise required or permitted by law.

I understand that pharmacies that ship my medication may be paid to share this information with the Program to help provide the offerings requested for me. Once my Protected Health Information has been disclosed to Kyowa Kirin, I understand that federal privacy laws no longer protect the information. However, Kyowa Kirin agrees to protect my Protected Health Information by using and disclosing it only for the purposes described in this authorization or as permitted by law.

I understand that I may refuse to sign this Authorization. My choice about whether to sign will not change the way my Healthcare Providers or Insurers treat me, but I will not have access to the Program and the services provided by Kyowa Kirin under the Program. If I refuse to sign the Authorization, or revoke my authorization later, I understand that this means I will not be able to participate or receive assistance from the Program.

This Authorization will last for a period of five (5) years (unless earlier termination is required by applicable state law). I understand that I may cancel this Authorization at any time in the future, except to the extent that actions have been taken in reliance on the authorization, by mailing a request to 135 Route 202/206, Suite 6 Bedminster, NJ 07921, via fax at 844-267-5848, or by calling 833-552-2737. I understand that revoking this Authorization will end further uses and disclosure of my Protected Health Information by the parties identified above except to the extent those uses and disclosures have been made in reliance upon this Authorization as permitted by applicable law. I am entitled to receive a copy of this Authorization.

The personal and health insurance I have provided on this form is complete and accurate to the best of my knowledge. I will update my information promptly if any of the information reflected on this Form changes by contacting the Program at 833-552-2737.

Name of Patient: _____ Signature: _____ Date: _____

Please Print

Patient Authorized Representative

I permit Kyowa Kirin Cares Support Services representatives to speak with the following person about this enrollment form. This includes discussing the status of my application, insurance and financial questions, any missing documentation and other issues related to my enrollment, insurance appeals, or any other treatment related issues. I may cancel this authorization at any time by calling: 833-552-2737.

Name of Authorized Representative: _____ Relationship to Patient: _____

Telephone Number: _____ Email: _____

By signing below, I, the patient named above, allow this representative to speak on my behalf on any matter regarding my enrollment with the Program.

Signature: _____ Date: _____

INDICATION

POTELIGEO® (mogamulizumab-kpkc) injection for intravenous infusion is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.

IMPORTANT SAFETY INFORMATION**Warnings and Precautions**

- **Dermatologic toxicity:** Monitor patients for rash throughout the course of treatment. For patients who experienced dermatologic toxicity in Trial 1, the median time to onset was 15 weeks, with 25% of cases occurring after 31 weeks. Interrupt POTELIGEO for moderate or severe rash (Grades 2 or 3). Permanently discontinue POTELIGEO for life-threatening (Grade 4) rash or for any Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).
- **Infusion reactions:** Most infusion reactions occur during or shortly after the first infusion. Infusion reactions can also occur with subsequent infusions. Monitor patients closely for signs and symptoms of infusion reactions and interrupt the infusion for any grade reaction and treat promptly. Permanently discontinue POTELIGEO for any life-threatening (Grade 4) infusion reaction.
- **Infections:** Monitor patients for signs and symptoms of infection and treat promptly.
- **Autoimmune complications:** Interrupt or permanently discontinue POTELIGEO as appropriate for suspected immune-mediated adverse reactions. Consider the benefit/risk of POTELIGEO in patients with a history of autoimmune disease.
- **Complications of allogeneic HSCT after POTELIGEO:** Increased risks of transplant complications have been reported in patients who received allogeneic HSCT after POTELIGEO. Follow patients closely for early evidence of transplant-related complications.

Adverse Reactions

- The most common adverse reactions (reported in ≥10% of patients) with POTELIGEO in the clinical trial were rash, including drug eruption (35%), infusion reaction (33%), fatigue (31%), diarrhea (28%), drug eruption (24%), upper respiratory tract infection (22%), musculoskeletal pain (22%), skin infection (19%), pyrexia (17%), edema (16%), nausea (16%), headache (14%), thrombocytopenia (14%), constipation (13%), anemia (12%), mucositis (12%), cough (11%), and hypertension (10%).

You are encouraged to report suspected adverse reactions to Kyowa Kirin, Inc. at 1-844-768-3544 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.